( Reuters) – German biotech BioNTech and U.S. drugmaker Pfizer Inc stated on Monday they would start an essential international research study to assess their lead COVID-19 vaccine prospect.
FILE PICTURE: A female holds a little bottle labeled with a “Vaccine COVID-19” sticker label and a medical syringe in this illustration taken April 10,2020 REUTERS/Dado Ruvic/
If the research study succeeds, the companies could submit the vaccine for regulatory approval as early as October, putting them on track to provide up to 100 million doses by the end of 2020 and 1.3 billion by the end of2021
Patients are each given two doses of the drugmakers’ vaccine to assist boost immunity, so the first 100 million dosages would immunize around 50 million individuals.
The study is expected to include about 120 websites globally and could include as much as 30,000 participants. It will include areas heavily affected by COVID-19
” The initiation of the Phase 2/3 trial is a significant step forward in our progress towards offering a prospective vaccine to assist fight the ongoing COVID-19 pandemic,” stated Kathrin Jansen, head of vaccine research study and development at Pfizer.
The trial hones in on Pfizer’s most appealing vaccine prospect, which it calls BNT162 b2. Earlier research studies removed other potential vaccines.
Pfizer has already has a contract to sell 100 million doses of its vaccine to the U.S. government and provide it the alternative to buy 500 million more. It is in talks with other governments, consisting of the European Union, about similar offers.
Over 150 vaccines are being developed versus COVID-19, which has declared almost 650,000 lives internationally and maimed economies.
The vaccine makes use of chemical messenger RNA to mimic the surface of the coronavirus and teach the immune system to recognize and neutralize it. The innovation has been around for years, there has never ever been an approved messenger RNA (mRNA) vaccine.
Moderna Inc likewise introduced an innovative phase trial with 30,000 individuals on Monday. Johnson & Johnson is beginning scientific trials this week.
Reporting by Vishwadha Chander in Bengaluru; Modifying by Maju Samuel, Richard Chang and Aurora Ellis